Stem definition | Drug id | CAS RN |
---|---|---|
4163 | 504-24-5 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 90.30 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.04 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 2.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 22, 2010 | FDA | ACORDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis relapse | 1791.47 | 14.85 | 787 | 36003 | 42177 | 50526157 |
Urinary tract infection | 1388.49 | 14.85 | 1207 | 35583 | 222813 | 50345521 |
Laboratory test abnormal | 1004.39 | 14.85 | 437 | 36353 | 22771 | 50545563 |
Balance disorder | 701.52 | 14.85 | 504 | 36286 | 70086 | 50498248 |
Multiple sclerosis | 674.55 | 14.85 | 319 | 36471 | 20174 | 50548160 |
Fall | 611.71 | 14.85 | 963 | 35827 | 333969 | 50234365 |
Urine analysis abnormal | 595.92 | 14.85 | 191 | 36599 | 4159 | 50564175 |
Gait disturbance | 554.41 | 14.85 | 611 | 36179 | 149394 | 50418940 |
Therapy cessation | 475.64 | 14.85 | 273 | 36517 | 25738 | 50542596 |
Muscular weakness | 378.39 | 14.85 | 403 | 36387 | 94610 | 50473724 |
Seizure | 265.39 | 14.85 | 375 | 36415 | 117499 | 50450835 |
Insomnia | 222.38 | 14.85 | 430 | 36360 | 174435 | 50393899 |
Escherichia urinary tract infection | 216.77 | 14.85 | 119 | 36671 | 10276 | 50558058 |
Muscle spasticity | 215.88 | 14.85 | 142 | 36648 | 17042 | 50551292 |
Peroneal nerve palsy | 195.98 | 14.85 | 84 | 36706 | 4199 | 50564135 |
Gait inability | 176.07 | 14.85 | 173 | 36617 | 36854 | 50531480 |
Dizziness | 155.53 | 14.85 | 578 | 36212 | 345791 | 50222543 |
Lymphocyte count decreased | 152.06 | 14.85 | 137 | 36653 | 26170 | 50542164 |
B-lymphocyte count decreased | 149.81 | 14.85 | 46 | 36744 | 864 | 50567470 |
Secondary progressive multiple sclerosis | 146.72 | 14.85 | 49 | 36741 | 1217 | 50567117 |
Memory impairment | 143.40 | 14.85 | 228 | 36562 | 79132 | 50489202 |
Inappropriate schedule of product administration | 139.01 | 14.85 | 213 | 36577 | 71618 | 50496716 |
Central nervous system lesion | 137.97 | 14.85 | 86 | 36704 | 9403 | 50558931 |
Hypoaesthesia | 136.68 | 14.85 | 292 | 36498 | 126965 | 50441369 |
Therapeutic response unexpected | 133.87 | 14.85 | 103 | 36687 | 15812 | 50552522 |
Flushing | 131.48 | 14.85 | 200 | 36590 | 66815 | 50501519 |
Rheumatoid arthritis | 129.11 | 14.85 | 4 | 36786 | 202546 | 50365788 |
Culture urine positive | 126.71 | 14.85 | 58 | 36732 | 3393 | 50564941 |
Paraesthesia | 124.63 | 14.85 | 272 | 36518 | 119971 | 50448363 |
Asthenia | 121.67 | 14.85 | 506 | 36284 | 318536 | 50249798 |
Toxicity to various agents | 117.40 | 14.85 | 10 | 36780 | 212489 | 50355845 |
Drug ineffective | 114.43 | 14.85 | 997 | 35793 | 818336 | 49749998 |
Urine leukocyte esterase positive | 113.91 | 14.85 | 51 | 36739 | 2832 | 50565502 |
Micturition urgency | 107.94 | 14.85 | 70 | 36720 | 8194 | 50560140 |
Dyspnoea | 106.53 | 14.85 | 146 | 36644 | 547462 | 50020872 |
Mobility decreased | 105.55 | 14.85 | 200 | 36590 | 79748 | 50488586 |
Pollakiuria | 105.17 | 14.85 | 107 | 36683 | 23744 | 50544590 |
Off label use | 95.76 | 14.85 | 123 | 36667 | 474303 | 50094031 |
Lymphopenia | 95.52 | 14.85 | 84 | 36706 | 15537 | 50552797 |
Urinary incontinence | 93.71 | 14.85 | 109 | 36681 | 28099 | 50540235 |
JC polyomavirus test positive | 90.31 | 14.85 | 33 | 36757 | 1076 | 50567258 |
Anaemia | 89.19 | 14.85 | 36 | 36754 | 252420 | 50315914 |
Systemic lupus erythematosus | 88.78 | 14.85 | 3 | 36787 | 140619 | 50427715 |
Product substitution issue | 84.77 | 14.85 | 75 | 36715 | 13982 | 50554352 |
Depression | 84.15 | 14.85 | 288 | 36502 | 165135 | 50403199 |
Head injury | 83.46 | 14.85 | 95 | 36695 | 23925 | 50544409 |
Trigeminal neuralgia | 82.94 | 14.85 | 42 | 36748 | 3073 | 50565261 |
T-lymphocyte count increased | 79.75 | 14.85 | 18 | 36772 | 91 | 50568243 |
Completed suicide | 79.29 | 14.85 | 4 | 36786 | 131885 | 50436449 |
Walking aid user | 77.96 | 14.85 | 52 | 36738 | 6381 | 50561953 |
Dysstasia | 75.04 | 14.85 | 78 | 36712 | 17741 | 50550593 |
CD4 lymphocytes increased | 74.27 | 14.85 | 18 | 36772 | 130 | 50568204 |
Joint swelling | 73.00 | 14.85 | 44 | 36746 | 245242 | 50323092 |
T-lymphocyte count decreased | 72.61 | 14.85 | 20 | 36770 | 251 | 50568083 |
Progressive multiple sclerosis | 71.03 | 14.85 | 25 | 36765 | 730 | 50567604 |
Neurogenic bladder | 68.79 | 14.85 | 36 | 36754 | 2821 | 50565513 |
Motor dysfunction | 67.58 | 14.85 | 52 | 36738 | 7979 | 50560355 |
Exposure during pregnancy | 65.96 | 14.85 | 6 | 36784 | 121009 | 50447325 |
Acute kidney injury | 64.97 | 14.85 | 43 | 36747 | 228015 | 50340319 |
Glossodynia | 62.27 | 14.85 | 6 | 36784 | 115563 | 50452771 |
Infusion related reaction | 61.79 | 14.85 | 23 | 36767 | 169534 | 50398800 |
Movement disorder | 61.70 | 14.85 | 70 | 36720 | 17562 | 50550772 |
Bladder disorder | 61.64 | 14.85 | 48 | 36742 | 7495 | 50560839 |
Red blood cells urine positive | 61.26 | 14.85 | 33 | 36757 | 2742 | 50565592 |
Dysgraphia | 59.60 | 14.85 | 32 | 36758 | 2641 | 50565693 |
Influenza like illness | 58.33 | 14.85 | 129 | 36661 | 57330 | 50511004 |
Arthralgia | 57.71 | 14.85 | 148 | 36642 | 438554 | 50129780 |
Neutropenia | 57.50 | 14.85 | 18 | 36772 | 147947 | 50420387 |
CD4 lymphocytes decreased | 57.13 | 14.85 | 25 | 36765 | 1314 | 50567020 |
White blood cells urine positive | 55.46 | 14.85 | 37 | 36753 | 4541 | 50563793 |
Primary progressive multiple sclerosis | 55.44 | 14.85 | 13 | 36777 | 80 | 50568254 |
Gait spastic | 55.15 | 14.85 | 16 | 36774 | 245 | 50568089 |
Product use issue | 54.92 | 14.85 | 20 | 36770 | 149455 | 50418879 |
Contraindicated product administered | 54.62 | 14.85 | 20 | 36770 | 148938 | 50419396 |
Maternal exposure during pregnancy | 54.43 | 14.85 | 24 | 36766 | 159754 | 50408580 |
CD8 lymphocytes decreased | 53.36 | 14.85 | 14 | 36776 | 144 | 50568190 |
Muscle spasms | 51.51 | 14.85 | 204 | 36586 | 125349 | 50442985 |
Loss of control of legs | 51.35 | 14.85 | 23 | 36767 | 1278 | 50567056 |
Treatment failure | 51.28 | 14.85 | 18 | 36772 | 137619 | 50430715 |
Temperature intolerance | 51.08 | 14.85 | 43 | 36747 | 7496 | 50560838 |
Product dose omission issue | 50.97 | 14.85 | 266 | 36524 | 183572 | 50384762 |
Hypotension | 50.59 | 14.85 | 58 | 36732 | 235411 | 50332923 |
Febrile neutropenia | 50.24 | 14.85 | 6 | 36784 | 97661 | 50470673 |
Magnetic resonance imaging abnormal | 48.22 | 14.85 | 28 | 36762 | 2690 | 50565644 |
Epilepsy | 47.48 | 14.85 | 68 | 36722 | 21499 | 50546835 |
Wound | 46.57 | 14.85 | 10 | 36780 | 105784 | 50462550 |
Lower respiratory tract infection | 46.23 | 14.85 | 7 | 36783 | 95194 | 50473140 |
Progressive multifocal leukoencephalopathy | 46.18 | 14.85 | 49 | 36741 | 11408 | 50556926 |
Dysuria | 46.16 | 14.85 | 78 | 36712 | 28426 | 50539908 |
Ataxia | 45.32 | 14.85 | 53 | 36737 | 13733 | 50554601 |
Rash | 45.08 | 14.85 | 165 | 36625 | 437306 | 50131028 |
Burning sensation | 44.96 | 14.85 | 101 | 36689 | 45345 | 50522989 |
Lymphocyte count abnormal | 44.90 | 14.85 | 17 | 36773 | 613 | 50567721 |
Feeling abnormal | 44.50 | 14.85 | 195 | 36595 | 125297 | 50443037 |
Diarrhoea | 44.49 | 14.85 | 249 | 36541 | 588227 | 49980107 |
Haemoglobin urine present | 44.24 | 14.85 | 18 | 36772 | 788 | 50567546 |
Sinusitis | 43.58 | 14.85 | 36 | 36754 | 170522 | 50397812 |
Adverse drug reaction | 43.13 | 14.85 | 112 | 36678 | 55110 | 50513224 |
Ankle fracture | 41.30 | 14.85 | 54 | 36736 | 15668 | 50552666 |
Urine abnormality | 41.07 | 14.85 | 35 | 36755 | 6203 | 50562131 |
Hemiparesis | 40.93 | 14.85 | 61 | 36729 | 19987 | 50548347 |
Escherichia test positive | 40.85 | 14.85 | 23 | 36767 | 2084 | 50566250 |
Urine odour abnormal | 39.22 | 14.85 | 32 | 36758 | 5341 | 50562993 |
Extra dose administered | 38.68 | 14.85 | 31 | 36759 | 5045 | 50563289 |
Nitrite urine present | 38.55 | 14.85 | 17 | 36773 | 910 | 50567424 |
Invasive ductal breast carcinoma | 38.53 | 14.85 | 33 | 36757 | 5888 | 50562446 |
Stomatitis | 38.18 | 14.85 | 13 | 36777 | 101331 | 50467003 |
Vitamin B12 increased | 38.15 | 14.85 | 15 | 36775 | 600 | 50567734 |
Relapsing-remitting multiple sclerosis | 37.84 | 14.85 | 14 | 36776 | 473 | 50567861 |
Arthropathy | 37.14 | 14.85 | 36 | 36754 | 157870 | 50410464 |
Weight increased | 36.93 | 14.85 | 56 | 36734 | 201835 | 50366499 |
Drug interaction | 36.87 | 14.85 | 55 | 36735 | 199566 | 50368768 |
Pneumonia | 36.83 | 14.85 | 146 | 36644 | 378255 | 50190079 |
Tremor | 36.59 | 14.85 | 173 | 36617 | 114730 | 50453604 |
Gastrointestinal haemorrhage | 36.50 | 14.85 | 5 | 36785 | 73316 | 50495018 |
Optic neuritis | 36.13 | 14.85 | 34 | 36756 | 6856 | 50561478 |
Pleural effusion | 35.24 | 14.85 | 8 | 36782 | 81446 | 50486888 |
Drug hypersensitivity | 35.03 | 14.85 | 82 | 36708 | 250928 | 50317406 |
General symptom | 34.98 | 14.85 | 22 | 36768 | 2441 | 50565893 |
Pancytopenia | 34.89 | 14.85 | 9 | 36781 | 84021 | 50484313 |
Swelling | 34.58 | 14.85 | 58 | 36732 | 200814 | 50367520 |
Urinary tract infection pseudomonal | 34.46 | 14.85 | 15 | 36775 | 778 | 50567556 |
Musculoskeletal disorder | 34.29 | 14.85 | 52 | 36738 | 17297 | 50551037 |
Vomiting | 33.66 | 14.85 | 197 | 36593 | 460561 | 50107773 |
Urinary tract infection bacterial | 32.97 | 14.85 | 26 | 36764 | 4133 | 50564201 |
Wheelchair user | 32.95 | 14.85 | 28 | 36762 | 4944 | 50563390 |
Drug intolerance | 32.67 | 14.85 | 69 | 36721 | 219035 | 50349299 |
Abdominal pain | 32.30 | 14.85 | 78 | 36712 | 236150 | 50332184 |
Acute disseminated encephalomyelitis | 32.16 | 14.85 | 10 | 36780 | 196 | 50568138 |
Hip fracture | 31.89 | 14.85 | 63 | 36727 | 25868 | 50542466 |
Platelet count decreased | 31.45 | 14.85 | 17 | 36773 | 100709 | 50467625 |
Product use in unapproved indication | 31.40 | 14.85 | 23 | 36767 | 115796 | 50452538 |
Cystitis | 31.38 | 14.85 | 87 | 36703 | 44477 | 50523857 |
Pain | 30.88 | 14.85 | 271 | 36519 | 578632 | 49989702 |
Respiratory failure | 30.56 | 14.85 | 14 | 36776 | 91167 | 50477167 |
Prescribed underdose | 30.39 | 14.85 | 47 | 36743 | 15902 | 50552432 |
Lymphocyte percentage decreased | 30.32 | 14.85 | 21 | 36769 | 2739 | 50565595 |
Cognitive disorder | 29.95 | 14.85 | 85 | 36705 | 44038 | 50524296 |
Tongue biting | 29.87 | 14.85 | 16 | 36774 | 1314 | 50567020 |
Blood immunoglobulin M decreased | 29.23 | 14.85 | 13 | 36777 | 710 | 50567624 |
B-lymphocyte count abnormal | 28.95 | 14.85 | 7 | 36783 | 50 | 50568284 |
Blister | 28.80 | 14.85 | 13 | 36777 | 85405 | 50482929 |
Glycosylated haemoglobin increased | 28.75 | 14.85 | 37 | 36753 | 10569 | 50557765 |
Sensory disturbance | 28.57 | 14.85 | 39 | 36751 | 11790 | 50556544 |
Muscle tightness | 28.08 | 14.85 | 36 | 36754 | 10244 | 50558090 |
Thrombocytopenia | 27.87 | 14.85 | 31 | 36759 | 127642 | 50440692 |
Cardiac arrest | 27.79 | 14.85 | 13 | 36777 | 83638 | 50484696 |
Generalised tonic-clonic seizure | 27.74 | 14.85 | 60 | 36730 | 26250 | 50542084 |
Hypokinesia | 27.60 | 14.85 | 39 | 36751 | 12178 | 50556156 |
Intentional overdose | 27.31 | 14.85 | 6 | 36784 | 62498 | 50505836 |
Headache | 26.96 | 14.85 | 517 | 36273 | 506018 | 50062316 |
Invasive lobular breast carcinoma | 26.85 | 14.85 | 12 | 36778 | 663 | 50567671 |
Overdose | 26.78 | 14.85 | 20 | 36770 | 99707 | 50468627 |
Stress | 26.71 | 14.85 | 93 | 36697 | 53700 | 50514634 |
Breast cancer | 26.59 | 14.85 | 80 | 36710 | 42810 | 50525524 |
Diplopia | 26.40 | 14.85 | 49 | 36741 | 19211 | 50549123 |
Coordination abnormal | 26.32 | 14.85 | 37 | 36753 | 11497 | 50556837 |
Limb discomfort | 26.20 | 14.85 | 56 | 36734 | 24301 | 50544033 |
Bacterial test positive | 26.11 | 14.85 | 24 | 36766 | 4699 | 50563635 |
Incontinence | 25.77 | 14.85 | 34 | 36756 | 9951 | 50558383 |
Decreased appetite | 25.40 | 14.85 | 69 | 36721 | 200854 | 50367480 |
Protein urine present | 25.30 | 14.85 | 25 | 36765 | 5352 | 50562982 |
Status epilepticus | 24.84 | 14.85 | 39 | 36751 | 13367 | 50554967 |
Fatigue | 24.84 | 14.85 | 681 | 36109 | 706920 | 49861414 |
Insurance issue | 24.79 | 14.85 | 18 | 36772 | 2530 | 50565804 |
Immune reconstitution inflammatory syndrome | 24.77 | 14.85 | 25 | 36765 | 5491 | 50562843 |
Hypoxia | 24.27 | 14.85 | 4 | 36786 | 51119 | 50517215 |
Pyrexia | 23.93 | 14.85 | 170 | 36620 | 380033 | 50188301 |
Urinary sediment present | 23.90 | 14.85 | 16 | 36774 | 1975 | 50566359 |
Urine ketone body present | 23.88 | 14.85 | 17 | 36773 | 2316 | 50566018 |
Hyponatraemia | 23.67 | 14.85 | 21 | 36769 | 96118 | 50472216 |
Urinary retention | 23.47 | 14.85 | 56 | 36734 | 26134 | 50542200 |
Oxygen saturation decreased | 23.39 | 14.85 | 12 | 36778 | 73236 | 50495098 |
Paraparesis | 23.37 | 14.85 | 16 | 36774 | 2048 | 50566286 |
Lower limb fracture | 23.08 | 14.85 | 39 | 36751 | 14207 | 50554127 |
Infection | 22.92 | 14.85 | 58 | 36732 | 172896 | 50395438 |
General physical health deterioration | 22.81 | 14.85 | 43 | 36747 | 142391 | 50425943 |
Blood thyroid stimulating hormone decreased | 22.67 | 14.85 | 21 | 36769 | 4151 | 50564183 |
Decreased interest | 22.30 | 14.85 | 18 | 36772 | 2958 | 50565376 |
Hyperkalaemia | 22.30 | 14.85 | 4 | 36786 | 48085 | 50520249 |
Skin laceration | 22.24 | 14.85 | 45 | 36745 | 18797 | 50549537 |
Lymphocyte percentage abnormal | 22.03 | 14.85 | 5 | 36785 | 26 | 50568308 |
Proteus test positive | 21.63 | 14.85 | 7 | 36783 | 157 | 50568177 |
Hypersensitivity | 21.54 | 14.85 | 82 | 36708 | 215079 | 50353255 |
International normalised ratio increased | 21.34 | 14.85 | 3 | 36787 | 43149 | 50525185 |
Back pain | 21.26 | 14.85 | 249 | 36541 | 219781 | 50348553 |
Urinary tract infection enterococcal | 21.00 | 14.85 | 16 | 36774 | 2418 | 50565916 |
Feeling hot | 20.53 | 14.85 | 69 | 36721 | 39133 | 50529201 |
Cystitis klebsiella | 20.51 | 14.85 | 7 | 36783 | 186 | 50568148 |
Human papilloma virus test positive | 20.46 | 14.85 | 9 | 36781 | 479 | 50567855 |
Red blood cell count abnormal | 20.42 | 14.85 | 11 | 36779 | 914 | 50567420 |
Asthma | 20.26 | 14.85 | 21 | 36769 | 89316 | 50479018 |
Urge incontinence | 20.12 | 14.85 | 10 | 36780 | 703 | 50567631 |
Cardiac failure congestive | 20.10 | 14.85 | 19 | 36771 | 84363 | 50483971 |
Impaired healing | 20.05 | 14.85 | 13 | 36777 | 69773 | 50498561 |
Psoriasis | 19.63 | 14.85 | 13 | 36777 | 68987 | 50499347 |
Initial insomnia | 19.08 | 14.85 | 21 | 36769 | 5094 | 50563240 |
Speech disorder | 19 | 14.85 | 63 | 36727 | 35485 | 50532849 |
Folliculitis | 18.77 | 14.85 | 3 | 36787 | 39222 | 50529112 |
Therapeutic response changed | 18.65 | 14.85 | 10 | 36780 | 823 | 50567511 |
Anaphylactic reaction | 18.58 | 14.85 | 8 | 36782 | 54047 | 50514287 |
Metabolic acidosis | 18.51 | 14.85 | 3 | 36787 | 38822 | 50529512 |
Urinary tract infection staphylococcal | 18.45 | 14.85 | 7 | 36783 | 254 | 50568080 |
Peripheral swelling | 18.41 | 14.85 | 82 | 36708 | 205854 | 50362480 |
Rectal haemorrhage | 18.34 | 14.85 | 3 | 36787 | 38555 | 50529779 |
Hypoglycaemia | 18.30 | 14.85 | 8 | 36782 | 53573 | 50514761 |
Cardiac failure | 18.25 | 14.85 | 17 | 36773 | 76023 | 50492311 |
Depressed mood | 17.92 | 14.85 | 60 | 36730 | 33963 | 50534371 |
Tachycardia | 17.91 | 14.85 | 28 | 36762 | 99735 | 50468599 |
Bone pain | 17.88 | 14.85 | 6 | 36784 | 47223 | 50521111 |
Living in residential institution | 17.62 | 14.85 | 8 | 36782 | 459 | 50567875 |
Neutrophil percentage increased | 17.34 | 14.85 | 15 | 36775 | 2712 | 50565622 |
Therapeutic product effect incomplete | 17.09 | 14.85 | 25 | 36765 | 91490 | 50476844 |
Urinary tract disorder | 17.00 | 14.85 | 14 | 36776 | 2366 | 50565968 |
Bladder dysfunction | 16.78 | 14.85 | 9 | 36781 | 741 | 50567593 |
Mean cell haemoglobin decreased | 16.67 | 14.85 | 16 | 36774 | 3307 | 50565027 |
CD4 lymphocyte percentage decreased | 16.61 | 14.85 | 3 | 36787 | 3 | 50568331 |
Multiple organ dysfunction syndrome | 16.44 | 14.85 | 8 | 36782 | 50329 | 50518005 |
Transferrin saturation decreased | 16.44 | 14.85 | 8 | 36782 | 537 | 50567797 |
Haematocrit abnormal | 16.41 | 14.85 | 9 | 36781 | 775 | 50567559 |
Citrobacter infection | 16.38 | 14.85 | 7 | 36783 | 347 | 50567987 |
Vitamin D decreased | 16.34 | 14.85 | 25 | 36765 | 8381 | 50559953 |
Postictal paralysis | 16.33 | 14.85 | 5 | 36785 | 93 | 50568241 |
Disease progression | 16.19 | 14.85 | 28 | 36762 | 95838 | 50472496 |
Intraductal proliferative breast lesion | 16.16 | 14.85 | 14 | 36776 | 2536 | 50565798 |
Death | 16.12 | 14.85 | 155 | 36635 | 325224 | 50243110 |
Hypertonic bladder | 16.11 | 14.85 | 15 | 36775 | 2985 | 50565349 |
Arthritis | 15.89 | 14.85 | 24 | 36766 | 86697 | 50481637 |
Electrocardiogram QT prolonged | 15.84 | 14.85 | 9 | 36781 | 51877 | 50516457 |
Injection site scar | 15.74 | 14.85 | 9 | 36781 | 840 | 50567494 |
Bacterial test | 15.60 | 14.85 | 10 | 36780 | 1147 | 50567187 |
Cardio-respiratory arrest | 15.54 | 14.85 | 10 | 36780 | 53882 | 50514452 |
Renal failure | 15.53 | 14.85 | 34 | 36756 | 106599 | 50461735 |
B-lymphocyte count increased | 15.50 | 14.85 | 5 | 36785 | 111 | 50568223 |
Dysarthria | 15.49 | 14.85 | 61 | 36729 | 37342 | 50530992 |
Focal dyscognitive seizures | 15.33 | 14.85 | 14 | 36776 | 2718 | 50565616 |
Decreased vibratory sense | 15.31 | 14.85 | 6 | 36784 | 238 | 50568096 |
Haematochezia | 15.21 | 14.85 | 5 | 36785 | 39877 | 50528457 |
Cough | 15.09 | 14.85 | 108 | 36682 | 241156 | 50327178 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis relapse | 899.12 | 20.15 | 288 | 12148 | 11131 | 29550960 |
Multiple sclerosis | 432.08 | 20.15 | 139 | 12297 | 5415 | 29556676 |
Laboratory test abnormal | 304.92 | 20.15 | 150 | 12286 | 18035 | 29544056 |
Balance disorder | 298.62 | 20.15 | 187 | 12249 | 35983 | 29526108 |
Urinary tract infection | 285.82 | 20.15 | 239 | 12197 | 72115 | 29489976 |
Gait disturbance | 258.50 | 20.15 | 227 | 12209 | 73122 | 29488969 |
Fall | 255.07 | 20.15 | 341 | 12095 | 176837 | 29385254 |
Muscle spasticity | 222.67 | 20.15 | 82 | 12354 | 4801 | 29557290 |
Drug ineffective | 197.09 | 20.15 | 454 | 11982 | 362716 | 29199375 |
Muscular weakness | 146.15 | 20.15 | 154 | 12282 | 61898 | 29500193 |
Insomnia | 130.39 | 20.15 | 173 | 12263 | 88588 | 29473503 |
Central nervous system lesion | 129.84 | 20.15 | 58 | 12378 | 5590 | 29556501 |
Mobility decreased | 126.71 | 20.15 | 97 | 12339 | 25683 | 29536408 |
Relapsing-remitting multiple sclerosis | 121.62 | 20.15 | 33 | 12403 | 699 | 29561392 |
Gait spastic | 118.83 | 20.15 | 32 | 12404 | 658 | 29561433 |
Therapy cessation | 112.20 | 20.15 | 72 | 12364 | 14390 | 29547701 |
Needle fatigue | 99.45 | 20.15 | 27 | 12409 | 573 | 29561518 |
B-lymphocyte count decreased | 98.19 | 20.15 | 26 | 12410 | 500 | 29561591 |
Movement disorder | 97.26 | 20.15 | 58 | 12378 | 10179 | 29551912 |
Ataxia | 95.72 | 20.15 | 61 | 12375 | 12042 | 29550049 |
Memory impairment | 95.68 | 20.15 | 96 | 12340 | 36374 | 29525717 |
Seizure | 85.76 | 20.15 | 146 | 12290 | 92977 | 29469114 |
Secondary progressive multiple sclerosis | 82.52 | 20.15 | 21 | 12415 | 343 | 29561748 |
Micturition urgency | 81.63 | 20.15 | 41 | 12395 | 5132 | 29556959 |
Hypertonic bladder | 75.88 | 20.15 | 27 | 12409 | 1429 | 29560662 |
Gait inability | 72.88 | 20.15 | 61 | 12375 | 18314 | 29543777 |
Monoparesis | 68.83 | 20.15 | 27 | 12409 | 1876 | 29560215 |
Pollakiuria | 66.76 | 20.15 | 56 | 12380 | 16860 | 29545231 |
Flushing | 66.43 | 20.15 | 71 | 12365 | 28921 | 29533170 |
Therapeutic response unexpected | 64.50 | 20.15 | 42 | 12394 | 8596 | 29553495 |
Peroneal nerve palsy | 63.53 | 20.15 | 28 | 12408 | 2611 | 29559480 |
Product substitution issue | 59.83 | 20.15 | 41 | 12395 | 9131 | 29552960 |
Acute kidney injury | 57.51 | 20.15 | 20 | 12416 | 265247 | 29296844 |
Trigeminal neuralgia | 57.25 | 20.15 | 20 | 12416 | 1002 | 29561089 |
JC polyomavirus test positive | 55.52 | 20.15 | 17 | 12419 | 559 | 29561532 |
Anaemia | 53.38 | 20.15 | 10 | 12426 | 200941 | 29361150 |
Hypotension | 53.08 | 20.15 | 9 | 12427 | 194345 | 29367746 |
Influenza like illness | 52.68 | 20.15 | 58 | 12378 | 24412 | 29537679 |
Hypoaesthesia | 52.02 | 20.15 | 86 | 12350 | 53381 | 29508710 |
Progressive multifocal leukoencephalopathy | 49.94 | 20.15 | 36 | 12400 | 8683 | 29553408 |
Dizziness | 48.33 | 20.15 | 182 | 12254 | 189502 | 29372589 |
Lymphocyte count decreased | 43.78 | 20.15 | 47 | 12389 | 19224 | 29542867 |
Asthenia | 43.32 | 20.15 | 192 | 12244 | 215058 | 29347033 |
Paraesthesia | 42.49 | 20.15 | 79 | 12357 | 53766 | 29508325 |
Toxicity to various agents | 41.36 | 20.15 | 11 | 12425 | 173650 | 29388441 |
Drug interaction | 39.22 | 20.15 | 17 | 12419 | 197368 | 29364723 |
Urinary incontinence | 38.86 | 20.15 | 41 | 12395 | 16440 | 29545651 |
Lymphocyte percentage decreased | 37.85 | 20.15 | 18 | 12418 | 1999 | 29560092 |
Inappropriate schedule of product administration | 37.30 | 20.15 | 67 | 12369 | 44405 | 29517686 |
Urine analysis abnormal | 36.49 | 20.15 | 17 | 12419 | 1803 | 29560288 |
Progressive multiple sclerosis | 36.32 | 20.15 | 10 | 12426 | 224 | 29561867 |
Dyspnoea | 36.15 | 20.15 | 51 | 12385 | 326681 | 29235410 |
Nocturia | 35.73 | 20.15 | 29 | 12407 | 8333 | 29553758 |
Off label use | 35.25 | 20.15 | 45 | 12391 | 300755 | 29261336 |
Neutropenia | 34 | 20.15 | 7 | 12429 | 131704 | 29430387 |
T-lymphocyte count decreased | 33.65 | 20.15 | 9 | 12427 | 180 | 29561911 |
White blood cells urine positive | 33.33 | 20.15 | 14 | 12422 | 1160 | 29560931 |
Dysarthria | 33.16 | 20.15 | 52 | 12384 | 30859 | 29531232 |
Vitamin B12 increased | 31.90 | 20.15 | 9 | 12427 | 221 | 29561870 |
Decreased vibratory sense | 31.74 | 20.15 | 10 | 12426 | 362 | 29561729 |
Cognitive disorder | 31.64 | 20.15 | 44 | 12392 | 23455 | 29538636 |
Renal failure | 31.24 | 20.15 | 6 | 12430 | 118593 | 29443498 |
Walking aid user | 30.24 | 20.15 | 14 | 12422 | 1463 | 29560628 |
CD8 lymphocytes decreased | 30.23 | 20.15 | 7 | 12429 | 75 | 29562016 |
Cystitis | 29.74 | 20.15 | 26 | 12410 | 8266 | 29553825 |
Thrombocytopenia | 29.43 | 20.15 | 10 | 12426 | 134813 | 29427278 |
Adverse drug reaction | 28.00 | 20.15 | 42 | 12394 | 23978 | 29538113 |
Bladder disorder | 26.97 | 20.15 | 16 | 12420 | 2778 | 29559313 |
Back pain | 25.02 | 20.15 | 97 | 12339 | 102187 | 29459904 |
Paraparesis | 24.98 | 20.15 | 13 | 12423 | 1751 | 29560340 |
Burning sensation | 24.76 | 20.15 | 32 | 12404 | 15906 | 29546185 |
Musculoskeletal stiffness | 24.72 | 20.15 | 51 | 12385 | 37407 | 29524684 |
Pancytopenia | 24.65 | 20.15 | 3 | 12433 | 83165 | 29478926 |
Dysstasia | 24.59 | 20.15 | 26 | 12410 | 10448 | 29551643 |
Muscle spasms | 24.13 | 20.15 | 71 | 12365 | 65011 | 29497080 |
General symptom | 23.93 | 20.15 | 10 | 12426 | 818 | 29561273 |
Herpes zoster | 23.57 | 20.15 | 44 | 12392 | 30008 | 29532083 |
Neurogenic bladder | 23.32 | 20.15 | 12 | 12424 | 1578 | 29560513 |
Erectile dysfunction | 23.17 | 20.15 | 33 | 12403 | 17976 | 29544115 |
Spinal cord injury cauda equina | 21.32 | 20.15 | 6 | 12430 | 146 | 29561945 |
Temperature intolerance | 21.30 | 20.15 | 14 | 12422 | 2907 | 29559184 |
Somatosensory evoked potentials abnormal | 21.09 | 20.15 | 6 | 12430 | 152 | 29561939 |
Depression | 21.01 | 20.15 | 81 | 12355 | 85066 | 29477025 |
Cardiac failure | 20.89 | 20.15 | 4 | 12432 | 79283 | 29482808 |
Platelet count decreased | 20.78 | 20.15 | 9 | 12427 | 104663 | 29457428 |
Urosepsis | 20.61 | 20.15 | 24 | 12412 | 10722 | 29551369 |
Fatigue | 20.44 | 20.15 | 213 | 12223 | 316608 | 29245483 |
T-lymphocyte count increased | 20.32 | 20.15 | 3 | 12433 | 0 | 29562091 |
Vitamin B6 deficiency | 20.28 | 20.15 | 6 | 12430 | 175 | 29561916 |
Generalised tonic-clonic seizure | 20.24 | 20.15 | 32 | 12404 | 19107 | 29542984 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis relapse | 2014.04 | 15.24 | 787 | 35764 | 40348 | 64421833 |
Urinary tract infection | 1670.37 | 15.24 | 1230 | 35321 | 230366 | 64231815 |
Laboratory test abnormal | 1620.75 | 15.24 | 582 | 35969 | 23481 | 64438700 |
Multiple sclerosis | 684.40 | 15.24 | 292 | 36259 | 18649 | 64443532 |
Urine analysis abnormal | 639.38 | 15.24 | 203 | 36348 | 5553 | 64456628 |
Fall | 632.43 | 15.24 | 962 | 35589 | 415864 | 64046317 |
Balance disorder | 608.79 | 15.24 | 449 | 36102 | 83477 | 64378704 |
Gait disturbance | 413.58 | 15.24 | 498 | 36053 | 171657 | 64290524 |
Therapy cessation | 327.42 | 15.24 | 213 | 36338 | 32276 | 64429905 |
Muscular weakness | 314.77 | 15.24 | 374 | 36177 | 126964 | 64335217 |
Muscle spasticity | 291.20 | 15.24 | 156 | 36395 | 16513 | 64445668 |
B-lymphocyte count decreased | 262.10 | 15.24 | 71 | 36480 | 1090 | 64461091 |
Escherichia urinary tract infection | 257.26 | 15.24 | 129 | 36422 | 11908 | 64450273 |
Seizure | 223.51 | 15.24 | 365 | 36186 | 166527 | 64295654 |
Insomnia | 194.50 | 15.24 | 378 | 36173 | 197458 | 64264723 |
Central nervous system lesion | 187.81 | 15.24 | 104 | 36447 | 11745 | 64450436 |
Gait inability | 181.19 | 15.24 | 167 | 36384 | 42201 | 64419980 |
Peroneal nerve palsy | 165.91 | 15.24 | 74 | 36477 | 5247 | 64456934 |
Lymphocyte count decreased | 157.91 | 15.24 | 152 | 36399 | 40547 | 64421634 |
Pollakiuria | 154.04 | 15.24 | 134 | 36417 | 31396 | 64430785 |
Gait spastic | 153.05 | 15.24 | 44 | 36507 | 848 | 64461333 |
Micturition urgency | 150.82 | 15.24 | 86 | 36465 | 10273 | 64451908 |
Culture urine positive | 146.53 | 15.24 | 63 | 36488 | 4088 | 64458093 |
Memory impairment | 143.51 | 15.24 | 208 | 36343 | 85474 | 64376707 |
Secondary progressive multiple sclerosis | 142.80 | 15.24 | 45 | 36506 | 1198 | 64460983 |
Toxicity to various agents | 139.83 | 15.24 | 20 | 36531 | 363493 | 64098688 |
Urine leukocyte esterase positive | 134.61 | 15.24 | 56 | 36495 | 3347 | 64458834 |
Relapsing-remitting multiple sclerosis | 130.99 | 15.24 | 41 | 36510 | 1067 | 64461114 |
Dizziness | 128.89 | 15.24 | 533 | 36018 | 429630 | 64032551 |
Hypoaesthesia | 124.80 | 15.24 | 256 | 36295 | 138852 | 64323329 |
Mobility decreased | 123.30 | 15.24 | 194 | 36357 | 85646 | 64376535 |
Therapeutic response unexpected | 123.07 | 15.24 | 91 | 36460 | 16910 | 64445271 |
Movement disorder | 122.87 | 15.24 | 101 | 36450 | 21899 | 64440282 |
Anaemia | 118.40 | 15.24 | 34 | 36517 | 378646 | 64083535 |
Asthenia | 110.31 | 15.24 | 507 | 36044 | 427537 | 64034644 |
Acute kidney injury | 109.84 | 15.24 | 59 | 36492 | 449181 | 64013000 |
Urinary incontinence | 107.48 | 15.24 | 117 | 36434 | 36034 | 64426147 |
T-lymphocyte count decreased | 106.27 | 15.24 | 29 | 36522 | 458 | 64461723 |
JC polyomavirus test positive | 105.81 | 15.24 | 36 | 36515 | 1226 | 64460955 |
Paraesthesia | 102.77 | 15.24 | 232 | 36319 | 134290 | 64327891 |
T-lymphocyte count increased | 102.66 | 15.24 | 21 | 36530 | 82 | 64462099 |
Dyspnoea | 98.62 | 15.24 | 160 | 36391 | 718514 | 63743667 |
Inappropriate schedule of product administration | 96.24 | 15.24 | 181 | 36370 | 92105 | 64370076 |
Trigeminal neuralgia | 96.16 | 15.24 | 43 | 36508 | 3066 | 64459115 |
Off label use | 93.40 | 15.24 | 134 | 36417 | 632672 | 63829509 |
White blood cells urine positive | 90.00 | 15.24 | 49 | 36502 | 5349 | 64456832 |
Progressive multifocal leukoencephalopathy | 88.05 | 15.24 | 77 | 36474 | 18155 | 64444026 |
Flushing | 86.70 | 15.24 | 158 | 36393 | 78490 | 64383691 |
Ataxia | 86.61 | 15.24 | 83 | 36468 | 22001 | 64440180 |
Febrile neutropenia | 86.20 | 15.24 | 5 | 36546 | 187652 | 64274529 |
Hypotension | 86.04 | 15.24 | 55 | 36496 | 380919 | 64081262 |
Needle fatigue | 83.29 | 15.24 | 25 | 36526 | 563 | 64461618 |
CD8 lymphocytes decreased | 83.14 | 15.24 | 21 | 36530 | 241 | 64461940 |
Completed suicide | 82.46 | 15.24 | 14 | 36537 | 224400 | 64237781 |
CD4 lymphocytes increased | 81.68 | 15.24 | 21 | 36530 | 260 | 64461921 |
Head injury | 80.19 | 15.24 | 96 | 36455 | 32746 | 64429435 |
Rheumatoid arthritis | 79.91 | 15.24 | 3 | 36548 | 164291 | 64297890 |
Neutropenia | 77.67 | 15.24 | 20 | 36531 | 239604 | 64222577 |
Red blood cells urine positive | 75.63 | 15.24 | 41 | 36510 | 4437 | 64457744 |
Lymphopenia | 71.01 | 15.24 | 80 | 36471 | 25577 | 64436604 |
Product substitution issue | 67.91 | 15.24 | 66 | 36485 | 17795 | 64444386 |
Drug interaction | 66.90 | 15.24 | 64 | 36487 | 362019 | 64100162 |
Lymphocyte percentage decreased | 66.07 | 15.24 | 38 | 36513 | 4611 | 64457570 |
Hypertonic bladder | 65.37 | 15.24 | 34 | 36517 | 3384 | 64458797 |
Dysstasia | 65.30 | 15.24 | 73 | 36478 | 23142 | 64439039 |
Vitamin B12 increased | 64.25 | 15.24 | 21 | 36530 | 630 | 64461551 |
CD4 lymphocytes decreased | 63.77 | 15.24 | 30 | 36521 | 2405 | 64459776 |
Neurogenic bladder | 63.54 | 15.24 | 34 | 36517 | 3585 | 64458596 |
Dysuria | 60.27 | 15.24 | 95 | 36456 | 41962 | 64420219 |
Monoparesis | 58.46 | 15.24 | 30 | 36521 | 2904 | 64459277 |
Motor dysfunction | 56.87 | 15.24 | 49 | 36502 | 11324 | 64450857 |
Progressive multiple sclerosis | 56.29 | 15.24 | 20 | 36531 | 776 | 64461405 |
Walking aid user | 55.56 | 15.24 | 38 | 36513 | 6243 | 64455938 |
Influenza like illness | 53.43 | 15.24 | 112 | 36439 | 61590 | 64400591 |
Bladder disorder | 52.70 | 15.24 | 40 | 36511 | 7727 | 64454454 |
Haemoglobin urine present | 51.03 | 15.24 | 19 | 36532 | 844 | 64461337 |
Depression | 49.92 | 15.24 | 221 | 36330 | 183070 | 64279111 |
Cystitis | 49.91 | 15.24 | 88 | 36463 | 42587 | 64419594 |
Pancytopenia | 48.29 | 15.24 | 11 | 36540 | 143298 | 64318883 |
Diarrhoea | 47.88 | 15.24 | 229 | 36322 | 722475 | 63739706 |
Primary progressive multiple sclerosis | 47.57 | 15.24 | 11 | 36540 | 84 | 64462097 |
Lymphocyte count abnormal | 47.03 | 15.24 | 18 | 36533 | 863 | 64461318 |
Nitrite urine present | 47.03 | 15.24 | 19 | 36532 | 1053 | 64461128 |
Gastrointestinal haemorrhage | 46.96 | 15.24 | 9 | 36542 | 132303 | 64329878 |
Drug ineffective | 45.80 | 15.24 | 698 | 35853 | 839549 | 63622632 |
Urine abnormality | 45.77 | 15.24 | 36 | 36515 | 7326 | 64454855 |
Glycosylated haemoglobin increased | 44.41 | 15.24 | 50 | 36501 | 15969 | 64446212 |
Product dose omission issue | 44.40 | 15.24 | 223 | 36328 | 194524 | 64267657 |
Ankle fracture | 44.39 | 15.24 | 48 | 36503 | 14662 | 64447519 |
Product use issue | 43.14 | 15.24 | 16 | 36535 | 151699 | 64310482 |
Thrombocytopenia | 43.14 | 15.24 | 38 | 36513 | 223763 | 64238418 |
Urinary tract infection bacterial | 42.99 | 15.24 | 30 | 36521 | 5091 | 64457090 |
Magnetic resonance imaging abnormal | 42.98 | 15.24 | 25 | 36526 | 3098 | 64459083 |
Escherichia test positive | 42.59 | 15.24 | 24 | 36527 | 2801 | 64459380 |
Bacterial test positive | 42.21 | 15.24 | 33 | 36518 | 6657 | 64455524 |
Joint swelling | 42.20 | 15.24 | 36 | 36515 | 215346 | 64246835 |
Urinary tract infection pseudomonal | 41.70 | 15.24 | 19 | 36532 | 1415 | 64460766 |
Loss of control of legs | 41.64 | 15.24 | 20 | 36531 | 1679 | 64460502 |
Hip fracture | 41.32 | 15.24 | 63 | 36488 | 27036 | 64435145 |
Invasive ductal breast carcinoma | 41.07 | 15.24 | 29 | 36522 | 5013 | 64457168 |
Muscle spasms | 40.65 | 15.24 | 173 | 36378 | 140850 | 64321331 |
Temperature intolerance | 40.13 | 15.24 | 35 | 36516 | 8220 | 64453961 |
Blood thyroid stimulating hormone decreased | 40.12 | 15.24 | 29 | 36522 | 5201 | 64456980 |
B-lymphocyte count abnormal | 39.12 | 15.24 | 9 | 36542 | 67 | 64462114 |
Decreased appetite | 38.99 | 15.24 | 62 | 36489 | 281227 | 64180954 |
Feeling abnormal | 38.58 | 15.24 | 164 | 36387 | 133438 | 64328743 |
Dysarthria | 38.32 | 15.24 | 96 | 36455 | 59310 | 64402871 |
Urine odour abnormal | 38.31 | 15.24 | 28 | 36523 | 5108 | 64457073 |
Status epilepticus | 38.29 | 15.24 | 54 | 36497 | 21609 | 64440572 |
Blood immunoglobulin M decreased | 38.27 | 15.24 | 16 | 36535 | 968 | 64461213 |
Platelet count decreased | 38.08 | 15.24 | 24 | 36527 | 167687 | 64294494 |
Multiple organ dysfunction syndrome | 37.95 | 15.24 | 6 | 36545 | 101407 | 64360774 |
Paraparesis | 37.82 | 15.24 | 24 | 36527 | 3478 | 64458703 |
Epilepsy | 37.73 | 15.24 | 68 | 36483 | 33463 | 64428718 |
Generalised tonic-clonic seizure | 37.63 | 15.24 | 75 | 36476 | 39782 | 64422399 |
Renal failure | 37.29 | 15.24 | 29 | 36522 | 181659 | 64280522 |
Pneumonia | 37.17 | 15.24 | 177 | 36374 | 559399 | 63902782 |
Lower respiratory tract infection | 36.79 | 15.24 | 5 | 36546 | 94609 | 64367572 |
General symptom | 36.52 | 15.24 | 20 | 36531 | 2208 | 64459973 |
Tremor | 36.10 | 15.24 | 173 | 36378 | 148057 | 64314124 |
Infusion related reaction | 35.37 | 15.24 | 25 | 36526 | 164442 | 64297739 |
Drug hypersensitivity | 35.29 | 15.24 | 50 | 36501 | 237765 | 64224416 |
Musculoskeletal disorder | 35.21 | 15.24 | 47 | 36504 | 17859 | 64444322 |
Acute disseminated encephalomyelitis | 35.04 | 15.24 | 11 | 36540 | 289 | 64461892 |
Nocturia | 34.69 | 15.24 | 37 | 36514 | 11128 | 64451053 |
Hemiparesis | 34.22 | 15.24 | 61 | 36490 | 29766 | 64432415 |
Urine ketone body present | 34.06 | 15.24 | 22 | 36529 | 3285 | 64458896 |
Hyponatraemia | 33.99 | 15.24 | 21 | 36530 | 148318 | 64313863 |
Protein urine present | 33.87 | 15.24 | 33 | 36518 | 8923 | 64453258 |
Hyperkalaemia | 33.59 | 15.24 | 8 | 36543 | 101121 | 64361060 |
Extra dose administered | 33.58 | 15.24 | 29 | 36522 | 6721 | 64455460 |
Hypoxia | 33.47 | 15.24 | 5 | 36546 | 88144 | 64374037 |
Immune reconstitution inflammatory syndrome | 33.00 | 15.24 | 38 | 36513 | 12432 | 64449749 |
Cardiac failure | 32.83 | 15.24 | 17 | 36534 | 132356 | 64329825 |
Abdominal pain | 32.82 | 15.24 | 81 | 36470 | 312294 | 64149887 |
Respiratory failure | 32.73 | 15.24 | 26 | 36525 | 161157 | 64301024 |
Neutrophil percentage increased | 32.63 | 15.24 | 24 | 36527 | 4421 | 64457760 |
Cardiac arrest | 32.37 | 15.24 | 24 | 36527 | 154040 | 64308141 |
Treatment failure | 32.08 | 15.24 | 13 | 36538 | 116803 | 64345378 |
Cardiac failure congestive | 32.04 | 15.24 | 17 | 36534 | 130563 | 64331618 |
Pleural effusion | 31.76 | 15.24 | 16 | 36535 | 126543 | 64335638 |
Drug intolerance | 31.54 | 15.24 | 36 | 36515 | 187956 | 64274225 |
Breast cancer | 31.39 | 15.24 | 58 | 36493 | 29090 | 64433091 |
International normalised ratio increased | 31.22 | 15.24 | 4 | 36547 | 79163 | 64383018 |
Cystitis klebsiella | 30.98 | 15.24 | 10 | 36541 | 288 | 64461893 |
Prescribed underdose | 30.51 | 15.24 | 44 | 36507 | 17971 | 64444210 |
Urosepsis | 30.40 | 15.24 | 49 | 36502 | 22045 | 64440136 |
Metabolic acidosis | 29.44 | 15.24 | 3 | 36548 | 70955 | 64391226 |
Cognitive disorder | 29.42 | 15.24 | 83 | 36468 | 55004 | 64407177 |
Rhabdomyolysis | 29.04 | 15.24 | 8 | 36543 | 91718 | 64370463 |
Weight increased | 28.63 | 15.24 | 48 | 36503 | 213300 | 64248881 |
Overdose | 28.50 | 15.24 | 29 | 36522 | 159537 | 64302644 |
Muscle tightness | 27.96 | 15.24 | 33 | 36518 | 11082 | 64451099 |
Oxygen saturation decreased | 27.73 | 15.24 | 13 | 36538 | 107163 | 64355018 |
Decreased vibratory sense | 27.69 | 15.24 | 11 | 36540 | 583 | 64461598 |
Wheelchair user | 27.24 | 15.24 | 22 | 36529 | 4650 | 64457531 |
Rash | 27.05 | 15.24 | 151 | 36400 | 458398 | 64003783 |
Burning sensation | 26.69 | 15.24 | 75 | 36476 | 49589 | 64412592 |
Back pain | 26.68 | 15.24 | 237 | 36314 | 249934 | 64212247 |
Urinary tract infection enterococcal | 26.63 | 15.24 | 18 | 36533 | 2900 | 64459281 |
Vitamin D decreased | 26.62 | 15.24 | 27 | 36524 | 7660 | 64454521 |
Sensory disturbance | 26.48 | 15.24 | 35 | 36516 | 13173 | 64449008 |
Hypoglycaemia | 26.36 | 15.24 | 9 | 36542 | 89883 | 64372298 |
Exposure during pregnancy | 26.08 | 15.24 | 6 | 36545 | 77669 | 64384512 |
CD8 lymphocyte percentage decreased | 25.91 | 15.24 | 4 | 36547 | 0 | 64462181 |
Urinary sediment present | 25.86 | 15.24 | 16 | 36535 | 2218 | 64459963 |
Stomatitis | 25.83 | 15.24 | 15 | 36536 | 109590 | 64352591 |
Vomiting | 25.66 | 15.24 | 195 | 36356 | 550922 | 63911259 |
CD8 lymphocytes increased | 25.59 | 15.24 | 6 | 36545 | 49 | 64462132 |
Cardio-respiratory arrest | 25.35 | 15.24 | 12 | 36539 | 98381 | 64363800 |
Invasive lobular breast carcinoma | 25.09 | 15.24 | 10 | 36541 | 535 | 64461646 |
Pericarditis | 25.04 | 15.24 | 3 | 36548 | 62513 | 64399668 |
Disease progression | 25.01 | 15.24 | 26 | 36525 | 141654 | 64320527 |
Monocyte percentage increased | 24.88 | 15.24 | 15 | 36536 | 1985 | 64460196 |
Insurance issue | 24.76 | 15.24 | 17 | 36534 | 2809 | 64459372 |
Intentional overdose | 24.71 | 15.24 | 10 | 36541 | 89934 | 64372247 |
Haematochezia | 24.66 | 15.24 | 4 | 36547 | 66369 | 64395812 |
Coordination abnormal | 24.54 | 15.24 | 36 | 36515 | 14928 | 64447253 |
Neutrophil count increased | 24.52 | 15.24 | 48 | 36503 | 25126 | 64437055 |
Decreased interest | 24.34 | 15.24 | 18 | 36533 | 3342 | 64458839 |
Lower limb fracture | 24.29 | 15.24 | 34 | 36517 | 13511 | 64448670 |
Headache | 23.94 | 15.24 | 427 | 36124 | 529040 | 63933141 |
Optic neuritis | 23.64 | 15.24 | 26 | 36525 | 8090 | 64454091 |
Hepatic function abnormal | 23.62 | 15.24 | 4 | 36547 | 64309 | 64397872 |
Arthralgia | 23.25 | 15.24 | 151 | 36400 | 442109 | 64020072 |
General physical health deterioration | 23.06 | 15.24 | 51 | 36500 | 204374 | 64257807 |
Human papilloma virus test positive | 23.04 | 15.24 | 9 | 36542 | 456 | 64461725 |
Urinary tract disorder | 23.03 | 15.24 | 17 | 36534 | 3149 | 64459032 |
Red blood cell count abnormal | 22.90 | 15.24 | 12 | 36539 | 1212 | 64460969 |
Pyrexia | 22.67 | 15.24 | 205 | 36346 | 558439 | 63903742 |
Vitamin B12 abnormal | 22.40 | 15.24 | 6 | 36545 | 88 | 64462093 |
Lymphocyte percentage abnormal | 22.00 | 15.24 | 5 | 36546 | 35 | 64462146 |
Glossodynia | 21.72 | 15.24 | 5 | 36546 | 64691 | 64397490 |
Feeling hot | 21.70 | 15.24 | 66 | 36485 | 45597 | 64416584 |
Urinary tract infection staphylococcal | 21.58 | 15.24 | 10 | 36541 | 774 | 64461407 |
Visual impairment | 21.42 | 15.24 | 91 | 36460 | 73986 | 64388195 |
Blood thyroid stimulating hormone increased | 21.40 | 15.24 | 24 | 36527 | 7630 | 64454551 |
Tongue biting | 21.38 | 15.24 | 13 | 36538 | 1747 | 64460434 |
Pulmonary oedema | 21.20 | 15.24 | 9 | 36542 | 78665 | 64383516 |
CD4 lymphocyte percentage decreased | 21.20 | 15.24 | 4 | 36547 | 9 | 64462172 |
Limb discomfort | 20.86 | 15.24 | 47 | 36504 | 27128 | 64435053 |
Mean cell haemoglobin increased | 20.65 | 15.24 | 16 | 36535 | 3186 | 64458995 |
Vitamin D abnormal | 20.57 | 15.24 | 6 | 36545 | 122 | 64462059 |
Ascites | 20.40 | 15.24 | 5 | 36546 | 61996 | 64400185 |
Blood urine present | 20.38 | 15.24 | 37 | 36514 | 18303 | 64443878 |
Septic shock | 20.18 | 15.24 | 18 | 36533 | 105419 | 64356762 |
Erectile dysfunction | 20.16 | 15.24 | 30 | 36521 | 12597 | 64449584 |
Product use in unapproved indication | 19.97 | 15.24 | 44 | 36507 | 176574 | 64285607 |
Urinary sediment abnormal | 19.83 | 15.24 | 6 | 36545 | 139 | 64462042 |
B-lymphocyte count increased | 19.75 | 15.24 | 6 | 36545 | 141 | 64462040 |
Glucose urine present | 19.68 | 15.24 | 12 | 36539 | 1620 | 64460561 |
Blood pressure fluctuation | 19.56 | 15.24 | 3 | 36548 | 51868 | 64410313 |
Spinal cord injury cauda equina | 19.55 | 15.24 | 6 | 36545 | 146 | 64462035 |
Dysgraphia | 19.51 | 15.24 | 16 | 36535 | 3455 | 64458726 |
Expanded disability status scale score increased | 19.42 | 15.24 | 8 | 36543 | 466 | 64461715 |
Sinusitis | 19.41 | 15.24 | 33 | 36518 | 145895 | 64316286 |
Vitamin B6 deficiency | 19.40 | 15.24 | 7 | 36544 | 284 | 64461897 |
Mean cell haemoglobin decreased | 19.08 | 15.24 | 17 | 36534 | 4105 | 64458076 |
Proteus test positive | 18.84 | 15.24 | 7 | 36544 | 309 | 64461872 |
Contraindicated product administered | 18.79 | 15.24 | 20 | 36531 | 107809 | 64354372 |
Urinary retention | 18.77 | 15.24 | 66 | 36485 | 49135 | 64413046 |
Fear of falling | 18.77 | 15.24 | 8 | 36543 | 508 | 64461673 |
Asthma | 18.53 | 15.24 | 16 | 36535 | 95209 | 64366972 |
Skin laceration | 18.48 | 15.24 | 42 | 36509 | 24375 | 64437806 |
Citrobacter infection | 18.47 | 15.24 | 9 | 36542 | 780 | 64461401 |
Rectal haemorrhage | 18.46 | 15.24 | 6 | 36545 | 61811 | 64400370 |
Somatosensory evoked potentials abnormal | 18.33 | 15.24 | 6 | 36545 | 181 | 64462000 |
Anaphylactic reaction | 18.27 | 15.24 | 8 | 36543 | 68656 | 64393525 |
Neuropathy peripheral | 18.13 | 15.24 | 24 | 36527 | 117501 | 64344680 |
Road traffic accident | 18.08 | 15.24 | 48 | 36503 | 30697 | 64431484 |
Coma | 17.95 | 15.24 | 14 | 36537 | 87601 | 64374580 |
Crystal urine present | 17.85 | 15.24 | 12 | 36539 | 1917 | 64460264 |
Bacterial test | 17.51 | 15.24 | 10 | 36541 | 1197 | 64460984 |
Swelling | 17.23 | 15.24 | 41 | 36510 | 160177 | 64302004 |
Stress | 17.22 | 15.24 | 74 | 36477 | 60460 | 64401721 |
Urobilinogen urine increased | 17.21 | 15.24 | 8 | 36543 | 624 | 64461557 |
Electrocardiogram QT prolonged | 17.17 | 15.24 | 12 | 36539 | 79436 | 64382745 |
Therapeutic product effect incomplete | 17.15 | 15.24 | 20 | 36531 | 103462 | 64358719 |
Haemorrhage | 17.13 | 15.24 | 12 | 36539 | 79339 | 64382842 |
Rash maculo-papular | 17.11 | 15.24 | 3 | 36548 | 47023 | 64415158 |
Musculoskeletal stiffness | 17.08 | 15.24 | 124 | 36427 | 123082 | 64339099 |
Tibia fracture | 17.04 | 15.24 | 17 | 36534 | 4728 | 64457453 |
Full blood count abnormal | 17.04 | 15.24 | 46 | 36505 | 29711 | 64432470 |
Nephrolithiasis | 17.01 | 15.24 | 59 | 36492 | 43624 | 64418557 |
Diplopia | 16.99 | 15.24 | 43 | 36508 | 26722 | 64435459 |
Therapy interrupted | 16.90 | 15.24 | 36 | 36515 | 20000 | 64442181 |
Speech disorder | 16.80 | 15.24 | 63 | 36488 | 48378 | 64413803 |
Angioedema | 16.77 | 15.24 | 7 | 36544 | 61814 | 64400367 |
Chronic kidney disease | 16.64 | 15.24 | 6 | 36545 | 57913 | 64404268 |
White matter lesion | 16.62 | 15.24 | 11 | 36540 | 1711 | 64460470 |
Therapeutic response changed | 16.59 | 15.24 | 9 | 36542 | 975 | 64461206 |
Lactic acidosis | 16.59 | 15.24 | 7 | 36544 | 61403 | 64400778 |
Lymphocyte count increased | 16.37 | 15.24 | 17 | 36534 | 4958 | 64457223 |
Urine uric acid decreased | 16.36 | 15.24 | 5 | 36546 | 120 | 64462061 |
Wrist fracture | 16.31 | 15.24 | 24 | 36527 | 9977 | 64452204 |
Dyspnoea exertional | 16.12 | 15.24 | 11 | 36540 | 73719 | 64388462 |
Focal dyscognitive seizures | 16.09 | 15.24 | 14 | 36537 | 3276 | 64458905 |
Hypokalaemia | 15.82 | 15.24 | 28 | 36523 | 121875 | 64340306 |
COVID-19 | 15.82 | 15.24 | 76 | 36475 | 65064 | 64397117 |
Renal impairment | 15.79 | 15.24 | 33 | 36518 | 134984 | 64327197 |
Respiratory distress | 15.76 | 15.24 | 5 | 36546 | 52326 | 64409855 |
Transferrin saturation decreased | 15.74 | 15.24 | 8 | 36543 | 759 | 64461422 |
Streptococcal urinary tract infection | 15.63 | 15.24 | 6 | 36545 | 290 | 64461891 |
CD4 lymphocytes abnormal | 15.60 | 15.24 | 4 | 36547 | 49 | 64462132 |
Urinary tract obstruction | 15.56 | 15.24 | 15 | 36536 | 4002 | 64458179 |
Incontinence | 15.55 | 15.24 | 26 | 36525 | 12055 | 64450126 |
Maternal exposure during pregnancy | 15.39 | 15.24 | 19 | 36532 | 95865 | 64366316 |
Urine cannabinoids increased | 15.28 | 15.24 | 3 | 36548 | 9 | 64462172 |
None
Source | Code | Description |
---|---|---|
ATC | N07XX07 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
FDA MoA | N0000175448 | Potassium Channel Antagonists |
FDA EPC | N0000192795 | Potassium Channel Blocker |
CHEBI has role | CHEBI:33289 | avicides |
CHEBI has role | CHEBI:71031 | orphan drugs |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D026902 | Potassium Channel Blockers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Multiple sclerosis | indication | 24700007 | DOID:2377 |
Seizure disorder | contraindication | 128613002 | |
Impaired renal function disorder | contraindication | 197663003 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.58 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-gated potassium channel | Ion channel | BLOCKER | IC50 | 4.05 | CHEMBL | CHEMBL | |||
Potassium voltage-gated channel subfamily C member 1 | Ion channel | BLOCKER | IC50 | 4.50 | IUPHAR | ||||
Potassium voltage-gated channel subfamily C member 2 | Ion channel | BLOCKER | IC50 | 4.60 | IUPHAR |
ID | Source |
---|---|
4029704 | VUID |
N0000180628 | NUI |
D04127 | KEGG_DRUG |
4025700 | VANDF |
4025705 | VANDF |
4029704 | VANDF |
C0000477 | UMLSCUI |
CHEBI:34385 | CHEBI |
4AP | PDB_CHEM_ID |
CHEMBL284348 | ChEMBL_ID |
DB06637 | DRUGBANK_ID |
2416 | IUPHAR_LIGAND_ID |
BH3B64OKL9 | UNII |
1727 | PUBCHEM_CID |
897018 | RXNORM |
170373 | MMSL |
26967 | MMSL |
NOCODE | MMSL |
d07546 | MMSL |
006829 | NDDF |
413355004 | SNOMEDCT_US |
80994002 | SNOMEDCT_US |
D015761 | MESH_DESCRIPTOR_UI |
7283 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dalfampridine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0479 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 27 sections |
dalfampridine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0509 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | NDA authorized generic | 27 sections |
Dalfampridine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2533 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 27 sections |
AMPYRA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10144-427 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | NDA | 27 sections |
Dalfampridine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-292 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
DALFAMPRIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-275 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Dalfampridine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-246 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
Dalfampridine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-246 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
Dalfampridine | Human Prescription Drug Label | 1 | 62756-429 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 27 sections |
DALFAMPRIDINE | Human Prescription Drug Label | 1 | 65862-863 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Dalfampridine | Human Prescription Drug Label | 1 | 67877-444 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
Dalfampridine | Human Prescription Drug Label | 1 | 67877-444 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |